Meeting News

PanOptica cites biological response for anti-VEGF eye drop

SAN FRANCISCO — In topline results of a phase 1/2 trial of PAN-90806 presented at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology meeting, PanOptica cited finding a biological response for the once-daily anti-VEGF topical eye drop formulation.

The double-masked, dose-ranging trial randomized 51 treatment-naive patients with wet AMD to receive three dose strengths of PAN-90806 monotherapy over a 12-week period.

The study showed 88% of patients who completed the study experienced either clinical improvement or stability of their disease. Drug safety was characterized as “reasonably safe and well tolerated, with no major or serious drug-related safety concerns or trends,” according to a company press release.

“The phase 1/2 trial results constitute the most robust set of data exploring a topical anti-VEGF eye drop as monotherapy, and the favorable safety profile and biological response to PAN-90806 support its continued clinical development in wet AMD and other neovascular eye diseases,” Paul G. Chaney, president and CEO of PanOptica, said.

Chaney said PanOptica has engaged in discussions with potential strategic partners regarding future development, registration and commercialization of the drug.

SAN FRANCISCO — In topline results of a phase 1/2 trial of PAN-90806 presented at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology meeting, PanOptica cited finding a biological response for the once-daily anti-VEGF topical eye drop formulation.

The double-masked, dose-ranging trial randomized 51 treatment-naive patients with wet AMD to receive three dose strengths of PAN-90806 monotherapy over a 12-week period.

The study showed 88% of patients who completed the study experienced either clinical improvement or stability of their disease. Drug safety was characterized as “reasonably safe and well tolerated, with no major or serious drug-related safety concerns or trends,” according to a company press release.

“The phase 1/2 trial results constitute the most robust set of data exploring a topical anti-VEGF eye drop as monotherapy, and the favorable safety profile and biological response to PAN-90806 support its continued clinical development in wet AMD and other neovascular eye diseases,” Paul G. Chaney, president and CEO of PanOptica, said.

Chaney said PanOptica has engaged in discussions with potential strategic partners regarding future development, registration and commercialization of the drug.

    See more from American Academy of Ophthalmology Meeting